ArticleDiscover oncology2025
FAM3B overexpression correlates with poor prognosis and immune dysregulation in colorectal cancer: insights from bioinformatics and Mendelian randomization analyses.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundColorectal cancer (CRC) ranks third in global cancer diagnoses and is the second leading cause of cancer-related deaths. Identifying novel therapeutic targets and effective prognostic markers is crucial to improve CRC outcomes. This study aimed to investigate the role of FAM3B in relation to clinicopathological features, prognosis, tumor microenvironment, and immune infiltration of CRC.
methodsWe obtained data from bioinformatics databases, immunohistochemical experiments, and two-sample Mendelian randomization analyses. Differential expression analysis, survival analysis, Cox regression, and tumor microenvironment/immune infiltration evaluation were performed. FAM3B expression patterns were validated by immunohistochemistry. The causal relationship between FAM3B and CRC risk was explored using SNP data obtained from IEU GWAS and FinnGen by calculating the MR-Egger regression, weighted median, and inverse-variance weighting estimations.
resultsFAM3B was significantly upregulated in CRC tissues compared to normal tissues (p < 0.001). High FAM3B expression was associated with poor prognosis (HR: 1.59, 95% CI 1.00-2.54, p < 0.05), advanced tumor stages, and metastasis. Patients with high FAM3B expression had lower overall survival rates compared to those with low expression. High FAM3B levels were correlated with increased tumor cell purity and specific immune infiltration, including higher levels of M1 macrophages and lower levels of CD8+ T cells, resting NK cells, and monocytes (p < 0.05). The multivariate Cox regression analysis confirmed FAM3B as an independent prognostic factor. Mendelian randomization analysis indicated a causal relationship between FAM3B and CRC risk (IVW method OR = 1.07, 95% CI 1.00-1.14, p = 0.035).
conclusionHigh FAM3B expression levels are correlated with poor prognosis and advanced tumor stages in CRC patients, likely influencing CRC development by regulating the tumor microenvironment characteristics. These findings suggest that FAM3B could be a potential CRC therapeutic target, and the constructed clinical predictive model offers new insights for the diagnosis and treatment of CRC patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.